tiprankstipranks
Zymeworks price target raised to $14 from $12 at Wells Fargo
The Fly

Zymeworks price target raised to $14 from $12 at Wells Fargo

Wells Fargo raised the firm’s price target on Zymeworks (ZYME) to $14 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).

Invest with Confidence:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App